European Patent Granted To Reviva's Brilaroxazine For Pulmonary Hypertension

Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical firm focusing on therapies for unmet medical needs in central nervous system (CNS) disorders, inflammatory conditions, and cardiometabolic diseases, announced today that it has been granted European Patent EP3244896 by the European Patent Office (EPO).

This patent covers the use of brilaroxazine for treating pulmonary hypertension (PH), expanding Reviva's patent portfolio which already includes protection in key markets such as the United States, China, and Japan. The European patent specifically addresses the use of brilaroxazine for treating PH and pulmonary arterial hypertension (PAH) in any patient, as well as treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD). Additionally, brilaroxazine has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA) for the treatment of PAH.

Laxminarayan Bhat, Ph.D., Founder, President, and CEO, said “This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension. Brilaroxazine has demonstrated a favourable clinical safety and tolerability profile in over 800 subjects to date from multiple clinical trials.

He further added, “A significant reduction in key proinflammatory biomarkers following brilaroxazine treatment was recently shown in a large, global, pivotal Phase 3 study in patients with schizophrenia. Building on this promising clinical data, potent anti-inflammatory and antifibrotic activities and significant reduction in pulmonary arterial pressure has been shown in translational animal models for PAH following brilaroxazine treatment, and we look forward to further evaluating brilaroxazine’s unique multi-modal mechanism of action with clinical development expansion opportunities in PH and PAH.”